Dyne Therapeutics stock rises after Raymond James upgrade to Strong Buy

Investing.com -- Dyne Therapeutics Inc (NASDAQ:DYN) stock jumped 4.1% after Raymond James analyst Martin Auster upgraded the company from Outperform to Strong Buy and raised the price target to $35.00 from $31.00.

The upgrade reflects increased confidence in the upcoming DYNE-251 registrational cohort readout expected in late 2025, with a potential Biologics License Application (BLA) filing in early 2026. Auster’s optimism is based on the differentiated profile of DYNE-251 compared to Exondys 51, confidence in a path to accelerated approval, and what he describes as an underappreciated market opportunity in exon 51 Duchenne muscular dystrophy (DMD).

According to the analyst, the DYNE-251 registrational cohort results could serve as a key catalyst for Dyne Therapeutics, potentially de-risking a $500-700 million-plus peak annual opportunity in the U.S. and over $1 billion worldwide. The results could also establish the company’s DMD pipeline as a dominant narrative and elevate floor value ahead of 2026 DM1 catalysts.

These DM1 catalysts include the DYNE-101 registrational cohort readout expected around mid-2026 and a BLA filing anticipated in late 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.